An Introduction to Vasculitis
Vasculitis encompasses a diverse group of rare disorders linked by inflammation of blood vessel walls, which may result in organ failure or death. Vasculitis is categorized by size of the predominant vessel involved and includes small-, medium-, and large-vessel vasculitis. The most common forms are giant cell arteritis and polymyalgia rheumatica. Vasculitis may be primary, with no known cause, or secondary to infection, drugs, toxins, inflammatory disorder or cancer. They have a broad range of clinical presentations that can be systemic or organ-specific, and are often similar to more common diseases, resulting in diagnostic delay and poor outcomes. Treatment options include corticosteroids, methotrexate, azathioprine, mycophenolate, cyclophosphamide, tocilizumab and rituximab.
Molecular phenotyping of giant cell arteritis patients based on the serum protein signature: Lisa Christ, EULAR 2023
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about her study which investigated the serum protein signature of clinically defined GCA […]
Molecular Phenotyping of Giant Cell Arteritis: Lisa Christ, EULAR 2023
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about the unmet needs in the pathogenesis of […]
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]
Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?
touchREVIEWS in RMD. 2022;1(2):46–9 DOI: https://doi.org/10.17925/RMD.2022.1.2.46
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a spectrum of disorders primarily affecting the small blood vessels in various organs. It often affects the kidneys, causing rapidly progressive renal failure due to necrotizing crescentic glomerulonephritis. Another major cause of mortality in AAV is life-threatening pulmonary haemorrhage. Historically, AAV has been divided into granulomatosis with polyangiitis […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Lisa Christ, ACR 2022: Tocilizumab and ultra-short glucocorticoids in giant cell arteritis – one year follow-up of GUSTO
The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment. This […]
Lisa Christ, ACR 2022: Giant cell arteritis – epidemiology, prognosis and current treatment options
Giant cell arteritis (GCA) is an inflammation of the arteries which causes multiple symptoms including head pain and tenderness and can result in vision loss. touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss the epidemiology and prognosis of GCA, the limitations of glucocorticoid treatment and the rationale for […]
Bhaskar Dasgupta, ACR 2022: A validation study of the Southend pre-test probability score
The southend pre-test probability score (SPTPS) was recently developed to estimate the probability of giant cell arteritis (GCA) based on symptoms, signs and lab findings. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discuss the validation study of SPTPS and how effective the score was in assessing […]
Bhaskar Dasgupta, ACR 2022: Challenges in the diagnosis of giant cell arteritis
Giant cell arteritis (GCA) presents differently in early stages of the disease, early diagnosis is vital in reducing more severe symptoms such as sight loss. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discuss the difficulties in diagnosing GCA and why early diagnosis is so crucial. This […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!